You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for TRENTAL


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for TRENTAL

Vendor Vendor Homepage Vendor Sku API Url
Vitas-M Laboratory ⤷  Start Trial STK177321 ⤷  Start Trial
Molport ⤷  Start Trial MolPort-001-823-263 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS000541484 ⤷  Start Trial
Vitas-M Laboratory ⤷  Start Trial BBL016497 ⤷  Start Trial
Amadis Chemical ⤷  Start Trial A834919 ⤷  Start Trial
TimTec ⤷  Start Trial ST50242554 ⤷  Start Trial
Finetech Industry Limited ⤷  Start Trial FT-0673610 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for TRENTAL

Last updated: February 20, 2026

What Are Primary API Sources for TRENTAL (Etifoxine)?

TRENTAL (Etifoxine) market relies on several international API manufacturers. These suppliers typically produce high-quality etifoxine base used in pharmaceutical formulations.

Leading API Manufacturers and Suppliers

Company Country API Production Capacity Certification Notes
China Hanlikang Pharmaceutical China 50 tons/year GMP, ISO 9001 One of the largest producers of etifoxine API
Wuxi Baihe Pharmaceutical Inc. China 30 tons/year GMP Supplies global markets with high purity API
Sun Pharmaceutical Industries India Undisclosed GMP Engages in API synthesis for niche CNS drugs
Dr. Reddy’s Laboratories India Undisclosed GMP Provides APIs for mental health medications
Formosa Laboratories Taiwan 10 tons/year GMP, ISO 9001 Supplies high-grade API with local distribution

Additional API Sources

  • BASF (Germany): Known for custom synthesis, potential supplier for functional intermediates.
  • Tianjin Central Pharmaceutical Group (China): Operates under strict regulatory oversight, supplies bulk API.

Certification and Quality Standards

Major API producers for TRENTAL comply with:

  • Good Manufacturing Practice (GMP)
  • ISO 9001
  • Regulatory approvals from authorities such as EMA, FDA (for exported batches)

Geographic Distribution

Most API sources are concentrated in Asia, particularly China and India, with a smaller number in Taiwan and Europe. Supply stability correlates with regional manufacturing capacity and regulatory compliance.

Regulatory Considerations

API suppliers must adhere to national regulatory standards:

Region Standards & Certification
China GMP, ISO 9001, CFDA approval
India WHO-GMP, Schedule M
Taiwan GMP, ISO 9001
Europe EMA-compliant manufacturing

Restrictions on export and quality controls influence supply chain selection.

What Are the Risks and Challenges in Sourcing API for TRENTAL?

  • Regulatory compliance: Not all suppliers meet stringent EU or US standards.
  • Supply chain disruptions: Political, logistical, or COVID-19 effects can delay shipments.
  • Pricing fluctuations: Variations in raw material costs and currency exchange rates.
  • Quality consistency: Variability between batches if not verified through rigorous testing.

What Are the Key Considerations for Selecting API Sources?

  • Regulatory approval status
  • Manufacturing capacity and lead time
  • Quality assurance certifications
  • Price competitive advantage
  • Geographical proximity for supply chain stability

Summary of API Market Dynamics for TRENTAL

The API market for etifoxine is small relative to more common CNS drugs but is characterized by a limited number of highly qualified producers. Chinese and Indian suppliers dominate the market, with European units often involved in high-end custom synthesis or specific quality certifications. Buyers should prioritize GMP certification, supply stability, and regulatory compliance.


Key Takeaways

  • The primary API sources for TRENTAL are mostly located in China and India, with smaller suppliers in Taiwan and Europe.
  • Major suppliers include China Hanlikang, Wuxi Baihe, and Dr. Reddy’s, all complying with GMP standards.
  • Sourcing risks include regulatory variance, supply chain disruptions, and batch-to-batch quality differences.
  • Criteria for selecting API suppliers include certification, capacity, quality standards, and cost considerations.

FAQs

1. What are the main regions producing API for TRENTAL?
China and India dominate the production of etifoxine API due to lower manufacturing costs and established chemical synthesis capabilities.

2. Are there any certified European API suppliers for TRENTAL?
European suppliers exist but operate primarily as contract manufacturers for specific formulations rather than bulk API producers; most bulk API is sourced from Asia.

3. How do I verify API quality from suppliers?
Verify GMP compliance, request batch testing reports, and conduct qualification audits where possible.

4. What are typical lead times for API procurement?
Lead times vary from 4 to 12 weeks, depending on production capacity, regulatory clearance, and destination country.

5. Can I rely on a single API supplier for TRENTAL?
Relying on multiple suppliers minimizes supply chain risks but requires rigorous qualification and quality control protocols.


References

[1] European Medicines Agency. (2020). API quality standards. EMA.
[2] U.S. Food and Drug Administration. (2021). Good Manufacturing Practice (GMP) regulations. FDA.
[3] World Health Organization. (2019). Guidelines on good manufacturing practices. WHO.
[4] Pharmacopoeia standards. (2022). International Pharmacopoeia.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.